<meta http-equiv="Content-Type" content="text/html;charset=utf-8" /><!DOCTYPE doctype html>
<html class xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <link href="/style.css" rel="stylesheet" type="text/css"/>
  <title id="pageTitle">
   # 061 Use of Psycho-Stimulants in Palliative Care, 2nd ed
  </title>
 </head>
 <body>
   
   <div id="mainBody">
    <!--/pageTopArea -->
    <div id="contentArea">
     <div id="contentContainer">
      <!--/toolContainer -->
      <div id="centerZone">
       <div id="titleBarContainer">
        <h1>
         # 061 Use of Psycho-Stimulants in Palliative Care, 2nd ed
        </h1>
       </div>
       <!--/titleBarContainer -->
       <div blockinfo="Freeform CenterZone BlockID1" class="Freeform CenterZone BlockID1">
        <p>
         <br/>
         <b>
          Author(s):
         </b>
         Vicki Jackson MD and Susan Block MD
        </p>
        <p>
         <b>
          Background
         </b>
         More than 95% of patients experience fatigue near the end of life. Chemotherapy, radiation, and administration of opioids all tend to increase tiredness. Depression is also a common cause of suffering at the end of life; about 25% of cancer patients with early stage disease develop depression, in advanced illness more than three-quarters of all patients have symptoms of depression.
        </p>
        <p>
         <b>
          Uses of Psycho-stimulants
         </b>
         Both fatigue and depression can be treated with one of the psycho-stimulants: dextroamphetamine, methylphenidate, or pemoline. Psycho-stimulants act rapidly and are well-tolerated. These medications have 6 potentially beneficial effects for patients with terminal illness:
        </p>
        <ul>
         <li>
          Mood elevation
         </li>
         <li>
          Improved energy
         </li>
         <li>
          Potentiate analgesic effect of opioids
         </li>
         <li>
          Counter opioid-induced sedation
         </li>
         <li>
          Increase appetite
         </li>
         <li>
          Improve cognition
         </li>
        </ul>
        <p>
         <b>
          Practical Tips
         </b>
         For depression, psycho-stimulants are the drug of choice for patients with a relatively short life expectancy of weeks to months because they act quickly, usually within 24-48 hours. Psycho-stimulants are generally safe. However, they should be used with caution in patients with heart disease or cognitive disturbances (e.g. delirium). Pemoline, a milder psycho-stimulant, can rarely cause hepatotoxicity, requiring regular monitoring of hepatic function. Some patients with severe depression and a longer life expectancy benefit from starting a psycho-stimulant and then transitioning to a selective serotonin reuptake inhibitor anti-depressant (SSRI). Psycho-stimulants are also useful to augment the action of SSRIs in patients with severe depression.
        </p>
        <hr/>
        <table align="center" border="1" cellpadding="3" cellspacing="0" width="100%">
         <tbody>
          <tr>
           <td>
            <b>
             Drug
            </b>
           </td>
           <td>
            <p>
             Onset of action
            </p>
           </td>
           <td>
            <p>
             Starting dose
            </p>
           </td>
           <td>
            <p>
             Usual Daily Dose
            </p>
           </td>
           <td>
            <p>
             Maximal Daily Dose
            </p>
           </td>
           <td>
            <p>
             Schedule
            </p>
            <hr/>
           </td>
          </tr>
          <tr>
           <td>
            <p>
             Dextroamphetamine
            </p>
            <p>
             Methylphenidate
            </p>
           </td>
           <td>
            <p>
             &lt;24hrs
            </p>
            <p>
             &lt;24hrs
            </p>
           </td>
           <td>
            <p>
             2.5-5mg
            </p>
            <p>
             2.5mg
            </p>
           </td>
           <td>
            <p>
             10-20mg
            </p>
            <p>
             5-10mg
            </p>
           </td>
           <td>
            <p>
             60-90mg
            </p>
            <p>
             60-90mg
            </p>
           </td>
           <td>
            <p>
             8am and
            </p>
            <p>
             noon*
            </p>
           </td>
          </tr>
          <tr>
           <td>
            Pemoline
           </td>
           <td>
            1-2 days
           </td>
           <td>
            18.75mg
           </td>
           <td>
            37.5mg
           </td>
           <td>
            150mg
           </td>
           <td>
            Twice daily
           </td>
          </tr>
         </tbody>
        </table>
        <p>
         <br/>
         *some patients may need a late afternoon booster dose (usually 1/2 the am dose)
        </p>
        <p>
         <b>
          References
         </b>
        </p>
        <ol>
         <li>
          Block S. Assessing and Managing Depression in the Terminally Ill Patient. Annals of Internal Medicine. 2000; 132(3):209-218.
         </li>
         <li>
          Roszans M, Dreisbach A, Lertora JJL, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Onc. 2002;20:335-339.
         </li>
        </ol>
        <p>
         <b>
          ACGME Competencies:
         </b>
         Medical Knowledge, Patient Care
        </p>
        <p>
         <b>
          Keyword(s):
         </b>
         Non-Pain Symptoms and Syndromes
        </p>
       </div>
      </div>
      <!--/centerZone -->
     </div>
     <!--/contentContainer -->
    </div>
    <!-- /contentArea -->
    <!--/bottomContainer -->
   </div>
   <!--/mainBody -->
   
 </body>
</html>
